305 related articles for article (PubMed ID: 28566329)
1. Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.
O'Steen S; Green DJ; Gopal AK; Orozco JJ; Kenoyer AL; Lin Y; Wilbur DS; Hamlin DK; Fisher DR; Hylarides MD; Gooley TA; Waltman A; Till BG; Press OW
Cancer Res; 2017 Jul; 77(14):3885-3893. PubMed ID: 28566329
[TBL] [Abstract][Full Text] [Related]
2. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
3. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
Sasi BK; Martines C; Xerxa E; Porro F; Kalkan H; Fazio R; Turkalj S; Bojnik E; Pyrzynska B; Stachura J; Zerrouqi A; Bobrowicz M; Winiarska M; Priebe V; Bertoni F; Mansouri L; Rosenquist R; Efremov DG
Leukemia; 2019 Oct; 33(10):2416-2428. PubMed ID: 30872780
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Prukova D; Andera L; Nahacka Z; Karolova J; Svaton M; Klanova M; Havranek O; Soukup J; Svobodova K; Zemanova Z; Tuskova D; Pokorna E; Helman K; Forsterova K; Pacheco-Blanco M; Vockova P; Berkova A; Fronkova E; Trneny M; Klener P
Clin Cancer Res; 2019 Jul; 25(14):4455-4465. PubMed ID: 31004002
[TBL] [Abstract][Full Text] [Related]
5. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199).
Phillips DC; Xiao Y; Lam LT; Litvinovich E; Roberts-Rapp L; Souers AJ; Leverson JD
Blood Cancer J; 2015 Nov; 5(11):e368. PubMed ID: 26565405
[TBL] [Abstract][Full Text] [Related]
6. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
[TBL] [Abstract][Full Text] [Related]
8. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.
Dey J; Deckwerth TL; Kerwin WS; Casalini JR; Merrell AJ; Grenley MO; Burns C; Ditzler SH; Dixon CP; Beirne E; Gillespie KC; Kleinman EF; Klinghoffer RA
Sci Rep; 2017 Dec; 7(1):18007. PubMed ID: 29269870
[TBL] [Abstract][Full Text] [Related]
9. Combining T-cell-based immunotherapy with venetoclax elicits synergistic cytotoxicity to B-cell lines in vitro.
Murakami S; Suzuki S; Hanamura I; Yoshikawa K; Ueda R; Seto M; Takami A
Hematol Oncol; 2020 Dec; 38(5):705-714. PubMed ID: 32822067
[TBL] [Abstract][Full Text] [Related]
10. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
Kerkhofs M; Vervloessem T; Stopa KB; Smith VM; Vogler M; Bultynck G
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708132
[TBL] [Abstract][Full Text] [Related]
11. Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
Davids MS; Roberts AW; Seymour JF; Pagel JM; Kahl BS; Wierda WG; Puvvada S; Kipps TJ; Anderson MA; Salem AH; Dunbar M; Zhu M; Peale F; Ross JA; Gressick L; Desai M; Kim SY; Verdugo M; Humerickhouse RA; Gordon GB; Gerecitano JF
J Clin Oncol; 2017 Mar; 35(8):826-833. PubMed ID: 28095146
[TBL] [Abstract][Full Text] [Related]
12. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.
Herzog LO; Walters B; Buono R; Lee JS; Mallya S; Fung A; Chiu H; Nguyen N; Li B; Pinkerton AB; Jackson MR; Schneider RJ; Ronai ZA; Fruman DA
Br J Cancer; 2021 Mar; 124(6):1098-1109. PubMed ID: 33318657
[TBL] [Abstract][Full Text] [Related]
13. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
14. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
15. Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
Teh TC; Nguyen NY; Moujalled DM; Segal D; Pomilio G; Rijal S; Jabbour A; Cummins K; Lackovic K; Blombery P; Thompson E; Ekert PG; Lessene G; Glaser SP; Huang DCS; Roberts AW; Guthridge MA; Wei AH
Leukemia; 2018 Feb; 32(2):303-312. PubMed ID: 28751770
[TBL] [Abstract][Full Text] [Related]
16. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
[TBL] [Abstract][Full Text] [Related]
17. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
18. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
[TBL] [Abstract][Full Text] [Related]
19. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM
Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331
[TBL] [Abstract][Full Text] [Related]
20. Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.
Lee YG; Guruprasad P; Ghilardi G; Pajarillo R; Sauter CT; Patel R; Ballard HJ; Hong SJ; Chun I; Yang N; Amelsberg KV; Cummins KD; Svoboda J; Gill S; Chong EA; North K; Church SE; Fraietta JA; Chang WJ; Lacey SF; Lu XM; Zhang Y; Whig K; Schultz DC; Cherry S; Gerson J; Schuster SJ; Porazzi P; Ruella M
Cancer Discov; 2022 Oct; 12(10):2372-2391. PubMed ID: 35904479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
